Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Marcus

Ann Arbor, MI Medical Doctor

NPI 1093831604 CMS profile 1395488

1500 E Medical Center Drive, Ann Arbor, MI 48109

Open in the dashboard

General payments

$880,248

786 records reported · program years 2019–2025

Research payments

$226,737

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$192,988 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Keith Marcus of Ann Arbor, MI is reported in the CMS Open Payments database as having received $880,248 across 786 general payments and $226,737 in research payments paid to them. Separately, studies naming them as principal investigator received $192,988 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $111,471 86
2025 Research $506 4
2024 General $102,250 117
2023 General $113,216 103
2023 Research $41,675 5
2022 General $79,416 79
2022 Research $184,557 4
2021 General $195,587 134
2020 General $95,709 52
2019 General $182,599 215

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Marcus
  • Michigan median
  • Middle half of Michigan
  • National median

In program year 2025, general payments to Keith Marcus were reported at $111,471. Among 33,118 Michigan profiles paid that year, the median was $162 and the middle half received between $49 and $568.

Show as a table
Year Keith Marcus Michigan median Middle half National median
2019 $182,599 $153 $47–$580 $163
2020 $95,709 $108 $35–$342 $114
2021 $195,587 $124 $35–$428 $132
2022 $79,416 $142 $43–$509 $149
2023 $113,216 $150 $46–$530 $160
2024 $102,250 $157 $47–$545 $164
2025 $111,471 $162 $49–$568 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $445,494 283 payments
  2. AbbVie, Inc. $258,497 243 payments
  3. Allergan Inc. $119,509 145 payments
  4. Merz North America, Inc. $56,244 106 payments
  5. Revance Therapeutics, Inc. $419 7 payments
  6. Endo Pharmaceuticals Inc. $68 1 payment
  7. Solta Medical, a division of Bausch Health US, LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $600,949 147 payments
  2. Consulting Fee $196,376 45 payments
  3. Travel and Lodging $59,055 131 payments
  4. Food and Beverage $23,772 450 payments
  5. Education $96 13 payments
Products named General payments · program years 2019–2025
  1. BOTOX $114,479 116 payments
  2. BOTOX COSMETIC $29,303 46 payments
  3. Xeomin Dermatology $14,906 53 payments
  4. OZURDEX $10,800 1 payment
  5. KYBELLA $1,950 1 payment
  6. ASCLERA $1,688 15 payments
  7. DAXXIFY $419 7 payments
  8. Xeomin musculoskeletal $368 4 payments
  9. VUITY $223 3 payments
  10. NATRELLE $132 1 payment
  11. Other $149 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Merz North America, Inc. $226,231 9 payments
  2. AbbVie, Inc. $506 4 payments

Records

799 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record